The Trials Are In, and Most Anti-Aging Peptides Missed Their Numbers

A fresh 2026 vendor-testing ranking landed this year, and it forced a second look at a category that has been coasting on marketing copy for years: anti-aging peptides. The report scored providers on lab testing and clinical oversight, not on sales copy. Read next to the actual trial data, most of what gets sold as longevity science falls apart fast. One compound did not.

Here is the news-desk version of that story, stripped of hype, built off the trials themselves.

The setup: what changed, and why the old guides are wrong

Most “best anti-aging peptide” roundups work backward from a sales page. This one works forward from data: randomized, placebo-controlled human trials, the kind regulators and researchers actually trust. Run every popular peptide through that filter and the field narrows fast. Treat each trial like an earnings report, something either beat expectations, missed them, or never got tested against a real benchmark, and the picture gets even clearer.

Score it that way and only one compound in this category posted a clean beat.

The scorecard, compound by compound

Epithalon. The claim is telomerase activation and longer life. The evidence is a study of 266 elderly subjects tracked over six to eight years, linked to lower mortality [3]. That’s a real number, but it comes from one research lineage, it’s decades old, and no independent modern trial has replicated it. The telomere mechanism itself is mostly cell and animal data. Call it: unconfirmed, single-source.

SS-31 (elamipretide). This is the miss that should worry anyone chasing the category. In the phase 3 MMPOWER-3 trial, 218 people with primary mitochondrial myopathy took 40 mg per day against placebo. It missed both primary endpoints, the six-minute walk test and a fatigue score [4][5]. A mitochondrial peptide, tested rigorously in patients with an actual mitochondrial disease, could not beat a sugar pill. That is a hard miss, not a rounding error.

Humanin. Genuinely interesting research, still in the lab. A 2020 paper found it extends lifespan in C. elegans through the daf-16/FOXO pathway, and runs notably higher in children of centenarians than in age-matched peers [6]. Promising signal, still preclinical. No human trial has tested it as a therapy.

GHK-Cu. The strongest human data in the group, with an asterisk. Topical studies show it boosting collagen production in around 70% of women, outperforming vitamin C and retinoic acid creams [7]. That’s a real win, for skin, applied to skin. It says nothing about the injected, whole-body rejuvenation the supplement world implies, because nobody tested that.

Thymosin alpha-1. The immune-system peptide with the most institutional backing, approved abroad for conditions like hepatitis. Its most recent stress test, the TESTS trial published in 2025, enrolled 1,106 sepsis patients and found no significant survival difference against placebo: a hazard ratio of 0.99 [8]. If the best-established immune peptide can’t move the needle in the immune emergency it should be built for, “rejuvenates the aging immune system” is an unearned headline.

Four compounds, four misses or asterisks. That leaves one.

The one clean beat: NMN

NMN, the NAD+ precursor, is the only name in this field with a randomized, double-blind, placebo-controlled human trial behind it. NAD+ is a coenzyme every cell needs for energy metabolism and DNA repair, and levels drop with age, which is the actual mechanism behind the longevity pitch [2].

The trial: published in 2023, 80 healthy middle-aged adults, doses of 300 mg, 600 mg, and 900 mg daily for 60 days, against placebo. Blood NAD+ rose significantly across every dose group. Six-minute walk distance improved significantly too, most at 600 mg and 900 mg [1].

That’s a measured result, in people, against placebo. It’s also a narrow one. The trial measured blood chemistry and a walking test over two months, nothing about lifespan or aging itself. NMN is the best-documented name in this category and the most modestly proven. Both things are true at once.

What it means: the question shifts from “which one” to “who’s accountable”

Once NMN clears the bar as the best-supported pick, the next question isn’t which retailer sells it cheapest. It’s who stands behind what actually ends up in the vial.

That split runs straight through the market. Licensed telehealth models put a clinician in the loop: an intake, a prescription when warranted, a licensed pharmacy compounding the product, follow-up care. Research-chemical retailers skip all of it. Add to cart, click past a “for research use only” disclaimer, and a powder arrives with no clinician, no prescription, and no one accountable for whether the label matches the contents. For a category this early-stage, that gap is the whole safety story, not a footnote.

The ranked picks

Scoring on oversight, sourcing, and honesty about the evidence, not price:

#1: FormBlends. A telehealth model, not a chemical retailer. Patients complete a medical assessment, a licensed physician reviews it and decides whether a protocol applies, and any compounded medication is prepared by a licensed 503A compounding pharmacy under USP standards, with care-team follow-up. It lists compounds people search for, including NAD+ in the context of cellular energy, and frames them around what they’re actually studied for, not as guaranteed reversal of aging. The trade-off: an intake process instead of instant checkout, and coverage limited to certain states. Separately, the 2026 vendor ranking mentioned above scored FormBlends first overall for three-method per-batch lab testing (HPLC, mass spectrometry, endotoxin analysis) with published purity figures, paired with its 503A pharmacy structure and required prescriber oversight [S1]. Two independent evaluations, same conclusion.

#2: HealthRX.com. Same operating logic: licensed clinical oversight, medications dispensed through proper pharmacy channels instead of sold as research chemicals. Compounded medications here are not FDA-approved finished drug products, same as anywhere in this category. Between FormBlends and HealthRX.com, the deciding factors are state licensing and which compounds each supports. Both sit inside a recognized telehealth framework, which is the qualifier that counts.

Below that line, a real medical tier still exists. MeriHealth, a women-focused telehealth provider, runs physician-supervised compounded GLP-1 and peptide protocols dispensed through licensed pharmacies, built around the specific hormonal and metabolic picture women bring to treatment. WomenRX operates on the same structural logic, licensed oversight, licensed pharmacy dispensing, a women’s-health-specific model. Between the two, state availability and compound selection are the practical tiebreakers.

Everything after that is a research-chemical retailer, not a medical provider. Sports Technology Labs sells research compounds including SARMs, which carry their own anti-doping baggage and are banned in several sports contexts. Swiss Chems offers research peptides and SARMs under identical research-use-only labeling. Biotech Peptides runs a peptide catalog under the same disclaimer. None involve a clinician, a prescription, or pharmacy dispensing, and none are reviewed by the FDA for identity, strength, or purity. Any certificate of analysis is one the seller chose to publish. There’s no way to rank these by quality, because there’s no independent, batch-level verification to rank against.

The bottom line

For the goal most people in this category are chasing, general healthspan, NMN and NAD+ biology is the best-supported single pick, and even that comes with a modest, well-defined result rather than a dramatic one [1][2]. The bigger lesson from this round of trials: SS-31 failed in a phase 3 study built for exactly its use case, and thymosin alpha-1 failed the same way in a 2025 sepsis trial. Confident marketing language, in this category, is the thing to distrust. Where the compound comes from, clinician, prescription, licensed pharmacy, is the variable that actually protects a buyer.

Questions people are asking

If I only chase one anti-aging peptide, which has the strongest human evidence? NMN, the NAD+ precursor. It’s the only compound in this category backed by a randomized, double-blind, placebo-controlled human trial. In a 2023 study of 80 healthy middle-aged adults, daily NMN at 300, 600, and 900 mg significantly raised blood NAD+ at every dose and significantly improved six-minute walk distance versus placebo, strongest at 600 and 900 mg [1].

Does raising NAD+ with NMN actually slow aging or extend lifespan? No. The 2023 trial tracked blood NAD+ and a walking test over 60 days, not aging or lifespan [1]. NAD+ is a coenzyme every cell relies on for energy metabolism and DNA repair, and it declines with age, which is the mechanism behind the longevity pitch [2]. A mechanism plus a short trial is not proof of life extension.

Why does this reporting treat SS-31 (elamipretide) and thymosin alpha-1 so skeptically when they sound impressive? Because both failed their toughest tests. In the phase 3 MMPOWER-3 trial, elamipretide at 40 mg per day missed its co-primary endpoints, the six-minute walk test and a fatigue score, in 218 people with primary mitochondrial myopathy [4]. Thymosin alpha-1, in the phase 3 TESTS trial, showed no significant 28-day mortality difference versus placebo across roughly 1,100 sepsis patients, hazard ratio 0.99 [8]. When a mitochondrial peptide can’t beat placebo in mitochondrial disease and a leading immune peptide can’t beat placebo in an immune emergency, anti-aging claims for healthy people are running ahead of the data.

Is GHK-Cu good for anti-aging? The human data is real but narrow. Topical studies show GHK-Cu improving collagen production in about 70% of women, beating vitamin C and retinoic acid creams [7]. That supports it as a topical skin ingredient. It does not support injected, systemic anti-aging use, because that’s not what the studies tested.

What about epithalon and its telomere claims? Treat them cautiously. The most-cited human evidence, a study of 266 elderly subjects followed six to eight years, links the compound to lower mortality [3], but it comes largely from a single research lineage without modern independent replication, and the telomere mechanism itself traces mostly to cell and animal work. An association in one long study isn’t proof of extended life.

Does the peptide choice matter more than the source it comes from? The source matters more. Even the best-supported compound here remains an early-stage, mostly-compounded option, not an approved drug. The protective question is who’s accountable for what’s actually in the product. A licensed telehealth and pharmacy model, clinician review, a prescription when warranted, a licensed 503A compounding pharmacy, outranks research-chemical retailers shipping powders labeled “for research use only” with no clinician, no prescription, and no FDA review of identity, strength, or purity.

Do peptides for anti-aging actually work, or is it mostly marketing?

Some show real effects, but it depends entirely on which peptide. Collagen-stimulating peptides like GHK-Cu have decent early human data for skin repair. Growth-hormone secretagogues have more clinical backing but also heavier regulatory scrutiny. The honest read: the evidence quality varies wildly across this category, and a lot of what’s sold online is well ahead of what trials actually show.

Are peptides for anti-aging safe to use long-term?

Safety varies by peptide, dose, and how it’s sourced. Topical collagen peptides have a long consumer track record. Injectable peptides, especially growth-hormone secretagogues, carry real risks including shifts in insulin sensitivity and possible tumor promotion in people with undiagnosed conditions. Long-term human safety data is thin for most compounds. Anyone considering injectables should work with a physician, not a research-chemical supplier.

What are the best peptides for anti-aging based on actual clinical evidence?

Ranked by evidence quality, collagen peptides for skin and joint tissue sit near the top, backed by multiple randomized trials. Epithalon and some growth-hormone peptides have interesting animal and small human data but far fewer rigorous trials. NAD+ precursors aren’t technically peptides, but they currently carry the deepest longevity trial pipeline. An honest ranking admits the field is young and no single peptide has a definitive long-term outcome trial in healthy humans.

Where should I buy peptides for anti-aging without getting burned by low-quality sources?

This is where most people trip up. Research-chemical sites sell peptides labeled “not for human use,” meaning zero oversight on purity or dosing accuracy. For injectable anti-aging peptides prescribed off-label, a physician-supervised compounding pharmacy is the accountable route, and providers like FormBlends operate in that regulated space. Topical peptides in cosmetic products carry lower risk but are still worth sourcing from brands that publish third-party testing.

References

1. Yi L, Maier AB, Tao R, et al. The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023. https://pubmed.ncbi.nlm.nih.gov/36482258/
2. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141. https://pubmed.ncbi.nlm.nih.gov/33353981/
3. Khavinson VK, et al. Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine (epithalon and elderly mortality follow-up work).
4. Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3):e238-e252.
5. Karaa A, Haas R, Goldstein A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221.
6. Yen K, Wan J, Mehta HH, et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY). 2020;12(11):11185-11199.
7. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018;19(7):1987.
8. Liu D, Xie J, Yu X, et al. The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025.

---

Written by Liam Zamora, science journalist. Following the evidence to its honest limits. Last reviewed June 2026.

Informational use only. Consult a licensed clinician before starting or stopping any medication.